卡维地洛对慢性心力衰竭合并肾功能不全患者的疗效观察  

Carvedilol in treatment of patients with chronic heart failure complicated by chronic renal dysfunction

作　　者：钱正明[1] 徐栩羚[1] 戴茵茵[1] 

机构地区：[1]杭州市萧山区第一人民医院心内科,311201

出　　处：《浙江医学》2010年第4期485-487,共3页Zhejiang Medical Journal

摘　　要：目的观察卡维地洛对慢性心力衰竭合并肾功能不全患者的临床疗效。方法将60例慢性心力衰竭合并肾功能不全的患者采用数字表分组法随机分为两组，治疗组在接受常规心力衰竭治疗的基础上加用卡维地洛直到目标剂量，对照组不用卡维地洛，其余治疗措施相同。比较治疗12周后两组患者心功能和肾功能的变化。结果治疗组患者治疗12周后左室舒张末期内径、左室收缩末期内径较治疗前明显缩小（均P〈0．05），左室射血分数较治疗前明显增高（P〈0.05），且均优于对照组（均P〈0．05）。治疗12周后血尿素氮、肌酐、β2-微球蛋白较对照组明显降低（均P〈0．05）。结论卡维地洛能明显改善慢性心力衰竭合并肾功能不全患者的心功能和肾功能。Objective To evaluate the clinical efficacy of carvedilol in treatment of patients with chronic heart failure （CHF） complicated by chronic renal dysfunction （CRF）. Methods Sixty CHF patients complicated with CRF were divided into two groups： control group （receiving regular treatment） and treatment group （receiving oral carvedilol in a ramped dose scheme based on regular treatment）. Clinical parameters including cardiac function and renal function of two groups were assessed before and after treatment, Results After 12 weeks of carvidilol therapy, the left ventricular end-diastolic dimension （LVEDD） and left ventricular end-systolic dimension （LVESD） were decreased significantly in treatment group （both P〈0.05）, while left ventricular ejection fraction （LVEF） improved （P〈0.05）; the blood urea nitrogen （BUN）, serum creatinine （Cr） and blood J52 -microglobulin （β2-MG） were decreased significantly （all P〈0.05）. All of these results in treatment group were better than those in control group （all P〈0.05）. Conclusion Carvedilol may improve both cardiac function and renal function in CHF patients with CRF.

关 键 词：卡维地洛 慢性心力衰竭 肾功能 疗效 

分 类 号：R541.6[医药卫生—心血管疾病]